APL is a strikingly curable leukemia when treated correctly, driven by a fusion protein called PML/RARA that makes the malignant promyelocytes exquisitely sensitive to two targeted agents: all-trans retinoic acid (ATRA), which forces the leukemic cells to mature, and arsenic trioxide (ATO), which degrades the fusion protein itself. In standard-risk patients, the combination cures more than 90 percent. But high-risk disease, defined by the Sanz classification as a white blood cell count above 10 × 10⁹ per liter, carries early mortality of 15 to 25 percent, compared with 5 to 10 percent in standard-risk patients. Most of those early deaths come from catastrophic bleeding, differentiation syndrome, and infection, not from uncontrolled leukemia.

The landmark APL0406 and AML17 trials established ATRA plus ATO as the standard of care for standard and intermediate-risk APL, but they excluded high-risk patients or included too few for separate analysis. Concerned that the targeted agents alone could not adequately reduce the enormous tumor burden of high leukocytosis, many centers continued to treat high-risk patients with intensive anthracycline-based induction, typically three or more doses of idarubicin or daunorubicin equivalents. Recent prospective studies, including the APOLLO trial and the chemotherapy-free APL15 trial, have begun to question whether that extra chemotherapy actually helps.

To settle the question, a team led by Mohamed M. Khamis of Mercy Hospital and Saint Louis University School of Medicine conducted a PRISMA-compliant systematic review registered with PROSPERO, searching PubMed and the Cochrane Library from 2000 through 2025. They defined reduced-intensity regimens as ATRA plus ATO with cytoreduction limited to a single dose of gemtuzumab ozogamicin (GO) at 6 to 9 mg/m², one or two doses of low-dose idarubicin at 12 mg/m² each, or hydroxyurea alone. Intensive regimens were defined as ATRA-based therapy with three or more anthracycline doses. The search identified 325 unique records, of which 17 studies providing 25 treatment arms met the inclusion criteria, yielding 449 patients on reduced-intensity arms and 874 on intensive arms.

The pooled complete remission rate was 92.3 percent for reduced-intensity induction versus 89.3 percent for intensive chemotherapy, a 3.0 percentage point difference that was not statistically significant. Heterogeneity was strikingly low in the reduced-intensity group, with an I² of 0 percent, indicating remarkably consistent results across studies, while the intensive group showed moderate heterogeneity at 56.1 percent. Early mortality, defined as death within 30 days, was 8.8 percent versus 10.4 percent, again not statistically different. Relapse rates were 3.9 percent versus 5.5 percent, favoring the gentler approach but not reaching significance.

The most compelling finding came from the two randomized controlled trials with documented event definitions. The AML17 trial randomized 57 high-risk patients to ATRA plus ATO plus GO versus ATRA plus idarubicin, reporting 5-year recurrence-free survival of 100 percent versus 83 percent. The APOLLO trial randomized 133 high-risk patients to ATRA plus ATO with limited idarubicin versus standard AIDA chemotherapy, reporting 2-year event-free survival of 88 percent versus 71 percent, with relapse rates of 1.8 percent versus 17 percent and serious adverse events in 32 percent versus 68 percent. Pooling the hazard ratios from these two trials yielded an event-free survival hazard ratio of 0.23, representing a 77 percent reduction in events favoring reduced-intensity induction.

An exploratory white blood cell-stratified analysis revealed perhaps the most mechanistically revealing pattern. When the researchers examined complete remission by median white blood cell count below or above 30 × 10⁹ per liter, the reduced-intensity complete remission rate remained stable, shifting by only 0.9 percentage points across strata. The intensive chemotherapy complete remission rate, by contrast, declined from 96.0 percent to 86.6 percent, a drop of 9.4 percentage points, at the highest white blood cell levels. This pattern suggests that ATRA plus ATO maintains efficacy even at extreme disease burden, where conventional chemotherapy shows diminishing returns due to treatment-related complications.

The mechanistic explanation lies in the unique biology of APL. Unlike de novo acute myeloid leukemia, where chemotherapy intensity correlates with disease control, PML/RARA-positive promyelocytes are uniquely vulnerable to targeted therapy regardless of presenting leukocytosis. ATRA induces differentiation of the malignant cells, while ATO degrades the fusion protein that drives the leukemia. This molecular susceptibility explains why reduced-intensity regimens maintain efficacy even at white blood cell counts of 30 × 10⁹ per liter or higher, where the included studies enrolled patients with counts reaching 339 × 10⁹ per liter. The authors note that a dedicated subgroup for white blood cell counts above 50 × 10⁹ per liter was not feasible because no included arm had a median count that high, but the white blood cell count of 30 × 10⁹ per liter stratum encompassed arms with ranges extending to extreme leukocytosis.

Real-world validation studies strengthen the meta-analytic conclusions. The HARMONY registry, encompassing 1,438 patients across diverse practice settings, demonstrated 7-year overall survival of 91 percent and relapse rates of only 3 percent with ATRA plus ATO, with outcomes independent of the Sanz risk score. A French multicenter cohort found 5-year overall survival of 89.9 percent versus 72.7 percent favoring ATRA plus ATO over chemotherapy in high-risk patients. These data, spanning different supportive care infrastructures and geographic regions, suggest that the meta-analytic findings generalize beyond controlled trial populations.

For cytoreduction, the authors recommend gemtuzumab ozogamicin as a single dose of 6 or 9 mg/m², which provides targeted promyelocyte reduction without prolonged myelosuppression. For centers without access to GO, low-dose idarubicin at one or two doses of 12 mg/m² each provides effective cytoreduction with substantially lower toxicity. Hydroxyurea represents an alternative strategy, particularly in resource-limited settings, and has demonstrated efficacy in the APL15 chemotherapy-free approach. The choice of agent should be individualized based on institutional access, patient comorbidities, and degree of leukocytosis. The authors acknowledge limitations, including the predominance of observational data with potential confounding by indication, treatment heterogeneity within the reduced-intensity group, and geographic variations in supportive care practices. However, sensitivity analyses restricted to the two randomized trials showed consistent and even stronger results, and leave-one-out analysis demonstrated that no single study disproportionately influenced the pooled estimates. The convergent evidence from randomized trials, observational studies, and real-world registries supports reduced-intensity ATRA plus ATO-based regimens using GO or low-dose anthracycline as the preferred first-line therapy for high-risk APL.

Subject of Research: Hematology

Article Title: Reduced-intensity versus intensive induction in high-risk acute promyelocytic leukemia: a systematic review and meta-analysis

Article References: Khamis, M. M., Guevara Rodriguez, N. A., & Kunwor, R. (2026). Reduced-intensity versus intensive induction in high-risk acute promyelocytic leukemia: a systematic review and meta-analysis. Frontiers in Hematology, 5, Article 1851998. https://doi.org/10.3389/frhem.2026.1851998

Image Credits: AI Generated

DOI: 10.3389/frhem.2026.1851998

Keywords: acute promyelocytic leukemia, ATRA, arsenic trioxide, meta-analysis, high-risk APL, event-free survival, hematology, Reduced-intensity, versus, intensive, induction, high-risk